Table 2.
Baseline patient comorbidities
| OTX-101 n = 1846 |
CsA n = 2248 |
LFT n = 3008 |
|
|---|---|---|---|
| Quan-CCI, n (%) | |||
| Mean ± SD | 0.7 ± 1.4 | 1.2 ± 1.8 | 1.0 ± 1.7 |
| Median (IQR) | 0.0 (0.0, 1.0) | 0.0 (0.0, 2.0) | 0.0 (0.0, 2.0) |
| Score 0 | 1199 (65.0) | 1128 (50.2) | 1670 (55.5) |
| Score 1–2 | 513 (27.8) | 729 (32.4) | 926 (30.8) |
| Score 3–4 | 90 (4.9) | 258 (11.5) | 276 (9.2) |
| Score ≥ 5 | 44 (2.4) | 133 (5.9) | 136 (4.5) |
| Other comorbiditiesa, n (%) | |||
| Eye-related comorbidities | 449 (24.3) | 466 (20.7) | 652 (21.7) |
| Blepharitis | 264 (14.3) | 240 (10.7) | 323 (10.7) |
| Visual disturbance | 154 (8.3) | 185 (8.2) | 251 (8.3) |
| Allergic conjunctivitis | 99 (5.4) | 97 (4.3) | 158 (5.3) |
| Major autoimmune disorders | 52 (2.8) | 96 (4.3) | 85 (2.8) |
| Rheumatoid arthritis | 52 (2.8) | 96 (4.3) | 85 (2.8) |
| Any other comorbidities | 722 (39.1) | 1146 (51.0) | 1427 (47.4) |
| Thyroid disease | 288 (15.6) | 485 (21.6) | 578 (19.2) |
| Anxiety | 277 (15.0) | 478 (21.3) | 619 (20.6) |
| Depression | 234 (12.7) | 450 (20.0) | 534 (17.8) |
| Fatigue | 204 (11.1) | 298 (13.3) | 430 (14.3) |
| Menopause | 121 (6.6) | 163 (7.3) | 235 (7.8) |
| Systemic lupus | 47 (2.5) | 68 (3.0) | 112 (3.7) |
| Medicationsb, n (%) | |||
| Antidepressant and anti-anxiety medication | 861 (46.6) | 1398 (62.2) | 1768 (58.8) |
| Eye-related medication | 823 (44.6) | 560 (24.9) | 829 (27.6) |
| CsA | 293 (15.9) | 241 (8.1) | |
| LFT | 236 (12.8) | 117 (5.2) | |
| Other eye-related medication | 474 (25.7) | 473 (21.1) | 646 (21.5) |
| High blood pressure medication | 748 (40.5) | 1201 (53.1) | 1470 (48.9) |
| Hormone replacement therapy | 473 (25.6) | 707 (31.5) | 839 (27.9) |
| Topical glaucoma medication | 191 (10.3) | 200 (8.9) | 300 (10.1) |
| Topical allergy medication | 162 (8.8) | 220 (9.8) | 290 (9.6) |
CsA Cyclosporine ophthalmic emulsion 0.05%, IQR Interquartile range, LFT Lifitegrast ophthalmic solution 5%, OTX-101 Cyclosporine ophthalmic solution 0.09%, Quan-CCI Quan-Charlson Comorbidity Index, SD Standard deviation
aPatient comorbidities any time prior to or on the index date were reported
bMedications received in the baseline period (3 months prior to the index date) were reported